Kết quả bước đầu nghiên cứu ứng dụng tế bào gốc trung mô trong điều trị bệnh nhân mạn do lupus ban đỏ

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Cẩm Hà Chế, Sĩ Sằng Đồng, Duy Thăng Nguyễn, Thị Diệu Ngân Phan, Thị Thuỳ Hoa Phan, Thất Trí Tôn

Ngôn ngữ: vie

Ký hiệu phân loại: 610 Medicine and health

Thông tin xuất bản: Tạp chí y học việt nam (tổng hội y học việt nam), 2022

Mô tả vật lý: 26-32

Bộ sưu tập: Metadata

ID: 489437

Thêm vào giỏ Liên kết toàn văn

Tóm tắt
Chủ đề

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus. Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease. Cell therapy has become an attractive therapeutic strategy for various types of diseases, and it has achieved certain curative effects in induction therapy in patients with SLE. Bone marrow MSCs from SLE patients exhibit impaired capabilities of migration, differentiation, and immune regulation and display senescent phenotype. Meanwhile, MSCs derived from adipose tissue (AT-MSCs), known as multipotent stem cells, are most commonly used in the clinical applications in recent years. The purpose of this study was to evaluate the efficacy of MSCs in the treatment of SLE by meta-analysis. In this research, we reported a 35year man diagnosed with lupus nephritis who infused ATMSCs to improve of LN. In this case, the results( )indicated that AT-MSC infusions had lower proteinuria at 1 month, 3 months, 4 months, 6 months, and 18 months. In conclusion, ATMSCs might be a promising therapeutic agent for patients lupus nephritisViêm thận lupus (LN) là biến chứng nghiêm trọng của lupus ban đỏ hệ thống (Systemic lupus erythematosus - SLE). Các chiến lược điều trị hiện tại vẫn chưa đạt yêu cầu về khả năng đáp ứng hoàn toàn của thận, ngăn ngừa tái phát, suy thận và tiến triển thành bệnh thận giai đoạn cuối. Liệu pháp tế bào đã trở thành một chiến lược điều trị hấp dẫn đối với nhiều loại bệnh khác nhau và nó đã thu được những kết quả nhất định trong điều trị bệnh SLE. Tế bào gốc trung mô tủy xương của bệnh nhân SLE có biểu hiện giảm khả năng di chuyển, biệt hóa, điều hòa miễn dịch và kiểu hình lão hoá sớm. Trong khi đó, tế bào gốc từ mỡ (AT-MSCs) là nguồn tế bào gốc đa năng, được sử dụng phổ biến nhất trong các ứng dụng lâm sàng trong những năm gần đây. Mục đích của nghiên cứu này là đánh giá hiệu quả của MSCs trong điều trị SLE bằng các phân tích tổng hợp. Trong nghiên cứu này, chúng tôi báo cáo một nam bệnh nhân 35 tuổi, được chẩn đoán viêm thận lupus đã truyền AT-MSCs để cải thiện LN. Trong thử nghiệm này, kết quả chỉ ra rằng sau ghép AT- MSCs bệnh nhân có protein niệu thấp hơn ở các thời điểm 1 tháng, 3 tháng, 4( )tháng, 6 tháng và 18 tháng. Kết luận, AT- MSCs có thể là một tác nhân điều trị đầy hứa hẹn cho bệnh viêm thận lupus.

Tạo bộ sưu tập với mã QR